187 related articles for article (PubMed ID: 24307395)
1. Epidermal growth factor receptor tyrosine-kinase inhibitor treatment resistance in non-small cell lung cancer: biological basis and therapeutic strategies.
Carrera S; Buque A; Azkona E; Aresti U; Calvo B; Sancho A; Arruti M; Nuño M; Rubio I; de Lobera AR; Lopez C; Vivanco GL
Clin Transl Oncol; 2014 Apr; 16(4):339-50. PubMed ID: 24307395
[TBL] [Abstract][Full Text] [Related]
2. Current Approaches in NSCLC Targeting K-RAS and EGFR.
Aran V; Omerovic J
Int J Mol Sci; 2019 Nov; 20(22):. PubMed ID: 31739412
[TBL] [Abstract][Full Text] [Related]
3. Epidermal growth factor receptor and notch signaling in non-small-cell lung cancer.
Pancewicz-Wojtkiewicz J
Cancer Med; 2016 Dec; 5(12):3572-3578. PubMed ID: 27770511
[TBL] [Abstract][Full Text] [Related]
4. Advances in targeting EGFR allosteric site as anti-NSCLC therapy to overcome the drug resistance.
Maity S; Pai KSR; Nayak Y
Pharmacol Rep; 2020 Aug; 72(4):799-813. PubMed ID: 32666476
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor inhibitors and antiangiogenic agents for the treatment of non-small cell lung cancer.
Horn L; Sandler A
Clin Cancer Res; 2009 Aug; 15(16):5040-8. PubMed ID: 19671872
[TBL] [Abstract][Full Text] [Related]
6. New Directions for Advanced Targeting Strategies of EGFR Signaling in Cancer.
Zhou Y; Takahashi JI; Sakurai H
Biol Pharm Bull; 2024; 47(5):895-903. PubMed ID: 38692865
[TBL] [Abstract][Full Text] [Related]
7. Tumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectives.
Cheng X; Chen H
Onco Targets Ther; 2014; 7():1689-704. PubMed ID: 25285017
[TBL] [Abstract][Full Text] [Related]
8. Second and third-generation epidermal growth factor receptor tyrosine kinase inhibitors in advanced nonsmall cell lung cancer.
Liao BC; Lin CC; Yang JC
Curr Opin Oncol; 2015 Mar; 27(2):94-101. PubMed ID: 25611025
[TBL] [Abstract][Full Text] [Related]
9. Immune checkpoint inhibitors for non-small-cell lung cancer: does that represent a 'new frontier'?
Pilotto S; Kinspergher S; Peretti U; Calio A; Carbognin L; Ferrara R; Brunelli M; Chilosi M; Tortora G; Bria E
Anticancer Agents Med Chem; 2015; 15(3):307-13. PubMed ID: 25382117
[TBL] [Abstract][Full Text] [Related]
10. Integrated analysis of ALK higher expression in human cancer and downregulation in LUAD using RNA molecular scissors.
Saifullah ; Tsukahara T
Clin Transl Oncol; 2022 Sep; 24(9):1785-1799. PubMed ID: 35486222
[TBL] [Abstract][Full Text] [Related]
11. Identification of somatic copy number variations in plasma cell free DNA correlating with intrinsic resistances to EGFR targeted therapy in T790M negative non-small cell lung cancer.
Zhu L; Liang J; Xia B; Xu Y; Qian Z; Ma S; Zhang S
J Thorac Dis; 2020 Mar; 12(3):883-892. PubMed ID: 32274156
[TBL] [Abstract][Full Text] [Related]
12. Comparative review of drug-drug interactions with epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small-cell lung cancer.
Xu ZY; Li JL
Onco Targets Ther; 2019; 12():5467-5484. PubMed ID: 31371986
[TBL] [Abstract][Full Text] [Related]
13. Opportunities and challenges of co-targeting epidermal growth factor receptor and autophagy signaling in non-small cell lung cancer.
Wang X; Li W; Zhang N; Zheng X; Jing Z
Oncol Lett; 2019 Jul; 18(1):499-506. PubMed ID: 31289521
[TBL] [Abstract][Full Text] [Related]
14. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
15. Epidermal growth factor receptor (EGFR) T790M mutation identified in plasma indicates failure sites and predicts clinical prognosis in non-small cell lung cancer progression during first-generation tyrosine kinase inhibitor therapy: a prospective observational study.
Zhang S; Zhu L; Xia B; Chen E; Zhao Q; Zhang X; Chen X; Chen X; Ma S
Cancer Commun (Lond); 2018 May; 38(1):28. PubMed ID: 29789021
[TBL] [Abstract][Full Text] [Related]
16. A bispecific enediyne-energized fusion protein targeting both epidermal growth factor receptor and insulin-like growth factor 1 receptor showing enhanced antitumor efficacy against non-small cell lung cancer.
Guo XF; Zhu XF; Cao HY; Zhong GS; Li L; Deng BG; Chen P; Wang PZ; Miao QF; Zhen YS
Oncotarget; 2017 Apr; 8(16):27286-27299. PubMed ID: 28460483
[TBL] [Abstract][Full Text] [Related]
17. Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Wang X; Goldstein D; Crowe PJ; Yang JL
Onco Targets Ther; 2016; 9():5461-73. PubMed ID: 27660463
[TBL] [Abstract][Full Text] [Related]
18. The Frequency of EGFR Mutation in Lung Adenocarcinoma and the Efficacy of Tyrosine Kinase Inhibitor Therapy in a Hungarian Cohort of Patients.
Sárosi V; Balikó Z; Smuk G; László T; Szabó M; Ruzsics I; Mezősi E
Pathol Oncol Res; 2016 Oct; 22(4):755-61. PubMed ID: 27105879
[TBL] [Abstract][Full Text] [Related]
19. 244-MPT overcomes gefitinib resistance in non-small cell lung cancer cells.
Zhang Y; Yao K; Shi C; Jiang Y; Liu K; Zhao S; Chen H; Reddy K; Zhang C; Chang X; Ryu J; Bode AM; Dong Z; Dong Z
Oncotarget; 2015 Dec; 6(42):44274-88. PubMed ID: 26517520
[TBL] [Abstract][Full Text] [Related]
20. Role of rebiopsy in relapsed non-small cell lung cancer for directing oncology treatments.
Jekunen AP
J Oncol; 2015; 2015():809835. PubMed ID: 25699082
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
